<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20250210214223&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20250210214223&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 11 Feb 2025 02:42:24 +0000</lastbuilddate>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Antagonizing HFpEF by Targeting Fibrosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928720/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 11;151(6):396-399. doi: 10.1161/CIRCULATIONAHA.124.072973. Epub 2025 Feb 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928720/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39928720</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072973>10.1161/CIRCULATIONAHA.124.072973</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928720</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Glynnis Garry Bann</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Antagonizing HFpEF by Targeting Fibrosis</dc:title>
<dc:identifier>pmid:39928720</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072973</dc:identifier>
</item>
<item>
<title>Response by Shen et al to Letter Regarding Article, "Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928719/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 11;151(6):e38. doi: 10.1161/CIRCULATIONAHA.124.072690. Epub 2025 Feb 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928719/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39928719</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072690>10.1161/CIRCULATIONAHA.124.072690</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928719</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Li Shen</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Shen et al to Letter Regarding Article, "Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF"</dc:title>
<dc:identifier>pmid:39928719</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072690</dc:identifier>
</item>
<item>
<title>Major Adverse Cardiovascular Events 1 Year After Discharge in Out-of-Hospital Cardiac Arrest Survivors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928718/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 11;151(6):421-423. doi: 10.1161/CIRCULATIONAHA.124.070680. Epub 2025 Feb 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928718/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39928718</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070680>10.1161/CIRCULATIONAHA.124.070680</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928718</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Sang-Min Kim</dc:creator>
<dc:creator>Sehee Kim</dc:creator>
<dc:creator>Ye-Jee Kim</dc:creator>
<dc:creator>Won Young Kim</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Major Adverse Cardiovascular Events 1 Year After Discharge in Out-of-Hospital Cardiac Arrest Survivors</dc:title>
<dc:identifier>pmid:39928718</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070680</dc:identifier>
</item>
<item>
<title>From the Literature</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928717/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 11;151(6):416-417. doi: 10.1161/CIRCULATIONAHA.125.073800. Epub 2025 Feb 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928717/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39928717</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.073800>10.1161/CIRCULATIONAHA.125.073800</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928717</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Tracy Hampton</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>From the Literature</dc:title>
<dc:identifier>pmid:39928717</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.073800</dc:identifier>
</item>
<item>
<title>Letter by Tunçez and Gürses Regarding Article, "Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928716/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 11;151(6):e37. doi: 10.1161/CIRCULATIONAHA.124.071627. Epub 2025 Feb 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928716/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39928716</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071627>10.1161/CIRCULATIONAHA.124.071627</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928716</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Abdullah Tunçez</dc:creator>
<dc:creator>Kadri Murat Gürses</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Tunçez and Gürses Regarding Article, "Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF"</dc:title>
<dc:identifier>pmid:39928716</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071627</dc:identifier>
</item>
<item>
<title>Cox Regression Model in Clinical Research: Overview of Key Properties and Interpretation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928715/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 11;151(6):337-339. doi: 10.1161/CIRCULATIONAHA.124.072956. Epub 2025 Feb 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928715/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39928715</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072956>10.1161/CIRCULATIONAHA.124.072956</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928715</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Andrea Bellavia</dc:creator>
<dc:creator>Sabina A Murphy</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cox Regression Model in Clinical Research: Overview of Key Properties and Interpretation</dc:title>
<dc:identifier>pmid:39928715</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072956</dc:identifier>
</item>
<item>
<title>Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928714/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk factor for astherosclerotic cardiovascular disease, with proinflammatory and prothrombotic mechanisms contributing to its atherogenicity. On an equimolar basis, Lp(a) is ~5 to 6 times more atherogenic than particles that have been widely associated with adverse cardiovascular outcomes, such as LDL...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 11;151(6):400-415. doi: 10.1161/CIRCULATIONAHA.124.069210. Epub 2025 Feb 10.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk factor for astherosclerotic cardiovascular disease, with proinflammatory and prothrombotic mechanisms contributing to its atherogenicity. On an equimolar basis, Lp(a) is ~5 to 6 times more atherogenic than particles that have been widely associated with adverse cardiovascular outcomes, such as LDL (low-density lipoprotein). Lp(a) can enter the vessel wall, leading to the accumulation of oxidized phospholipids in the arterial intima, which are crucial for initiating plaque inflammation and triggering vascular disease progression. In addition, Lp(a) may cause atherothrombosis through interactions between apoA (apolipoprotein A) and the platelet PAR-1 (protease-activated receptor 1) receptor, as well as competitive inhibition of plasminogen. Because Lp(a) is mostly determined on genetic bases, a 1-time assessment in a lifetime can suffice to identify patients with elevated levels. Mendelian randomization studies and post hoc analyses of randomized trials of LDL cholesterol-lowering drugs showed a causal link between Lp(a) concentrations and cardiovascular outcomes, with therapeutic reduction of Lp(a) expected to contribute to estimated cardiovascular risk mitigation. Many Lp(a)-lowering drugs, including monoclonal antibodies, small interfering ribonucleic acids, antisense oligonucleotides, small molecules, and gene editing compounds, are at different stages of clinical investigation and show promise for clinical use. In particular, increased Lp(a) testing and treatment are expected to have a substantial impact at the population level, enabling the identification of high-risk individuals and the subsequent prevention of a large number of cardiovascular events. Ongoing phase 3 trials will further elucidate the cardiovascular benefits of Lp(a) reduction over the long term, offering potential avenues for targeted interventions and improved cardiovascular outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928714/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39928714</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069210>10.1161/CIRCULATIONAHA.124.069210</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928714</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Antonio Greco</dc:creator>
<dc:creator>Simone Finocchiaro</dc:creator>
<dc:creator>Marco Spagnolo</dc:creator>
<dc:creator>Denise Cristiana Faro</dc:creator>
<dc:creator>Maria Sara Mauro</dc:creator>
<dc:creator>Carmelo Raffo</dc:creator>
<dc:creator>Giuseppe Sangiorgio</dc:creator>
<dc:creator>Antonino Imbesi</dc:creator>
<dc:creator>Claudio Laudani</dc:creator>
<dc:creator>Placido Maria Mazzone</dc:creator>
<dc:creator>Nicola Ammirabile</dc:creator>
<dc:creator>Daniele Giacoppo</dc:creator>
<dc:creator>Davide Landolina</dc:creator>
<dc:creator>Davide Capodanno</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects</dc:title>
<dc:identifier>pmid:39928714</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069210</dc:identifier>
</item>
<item>
<title>Fibroblast growth factor 5: a novel biomarker for familial hypercholesterolaemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928422/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This analysis suggests that FGF-5 could be a biomarker to discriminate individuals living with FH from HC individuals.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 10:ehaf045. doi: 10.1093/eurheartj/ehaf045. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Identification of individuals affected by familial hypercholesterolaemia (FH) is suboptimal when genetic tests are unavailable. Relying only on low-density lipoprotein cholesterol (LDL-C) is challenging as it may not allow distinguishing individuals with FH from hypercholesterolaemic (HC) individuals from the general population. The aim of this study was to determine whether biomarkers associated with cardiovascular disease and/or inflammation identify FH individuals and distinguish them from HC individuals.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A panel of 264 proteins in plasma was measured and machine learning was used to search for those that can distinguish FH individuals, either genetically proven (genFH) or clinically diagnosed (clinFH) from HC and control individuals.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Both genFH and clinFH had elevated plasma levels of fibroblast growth factor 5 (FGF-5) compared with controls (mean area under the curve [AUC] >; .990 for both, P &lt; .001) or HC individuals (mean AUC >;.990, P &lt; .001), even after matching for LDL-C levels. An immunoenzymatic assay confirmed that FGF-5 was elevated in genFH and clinFH in all cohorts analysed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This analysis suggests that FGF-5 could be a biomarker to discriminate individuals living with FH from HC individuals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928422/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39928422</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf045>10.1093/eurheartj/ehaf045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928422</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Andrea Baragetti</dc:creator>
<dc:creator>Asiiat S Alieva</dc:creator>
<dc:creator>Liliana Grigore</dc:creator>
<dc:creator>Fabio Pellegatta</dc:creator>
<dc:creator>Andrea Lupi</dc:creator>
<dc:creator>Chiara Scrimali</dc:creator>
<dc:creator>Angelo B Cefalù</dc:creator>
<dc:creator>Barbara A Hutten</dc:creator>
<dc:creator>Albert Wiegman</dc:creator>
<dc:creator>Paul Knaapen</dc:creator>
<dc:creator>Michiel J Bom</dc:creator>
<dc:creator>Nick S Nurmohamed</dc:creator>
<dc:creator>Olga Reutova</dc:creator>
<dc:creator>Alexandra Konradi</dc:creator>
<dc:creator>Evgeny Shlyakhto</dc:creator>
<dc:creator>Erik S G Stroes</dc:creator>
<dc:creator>Maurizio Averna</dc:creator>
<dc:creator>Alberico L Catapano</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Fibroblast growth factor 5: a novel biomarker for familial hypercholesterolaemia</dc:title>
<dc:identifier>pmid:39928422</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf045</dc:identifier>
</item>
<item>
<title>Hypertrophic cardiomyopathy: prevalence of disease-specific red flags</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928417/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Red flags are a common finding in patients presenting with HCM, most commonly non-cardiac in non-sarcomeric aetiology and cardiac in sarcomeric HCM. Over 34% of RF, most relevant to rare HCM phenocopies, can be potentially detected in a generalist setting. Investing in high-touch-low tech, widespread awareness for HCM-related RF may provide substantial advantage in terms of diagnostic yield and appropriate use of resources.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 10:ehaf026. doi: 10.1093/eurheartj/ehaf026. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The European Society of Cardiology guidelines recommend a systematic search for diagnostic clues or 'red flags' (RFs) in patients with hypertrophic cardiomyopathy (HCM) to better tailor disease management. To date, the prevalence and clinical significance of RF associated with HCM phenotypes in different clinical settings are unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The study cohort comprised 818 patients with a clinical diagnosis of HCM [479 (62%) males, mean age 49 ± 21 years] referred to four European centres. Pre-specified RFs were categorized into one of five domains: (i) family history; (ii) physical examination; (iii) electrocardiography; (iv) echocardiography; and (v) laboratory.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 318 (39%) patients had a pathogenic or likely pathogenic sarcomere gene variant; 240 (29%) a TTR and GLA variant; 154 (19%) a syndromic cause; and 106 (13%) no identifiable cause. In the overall cohort, 2979 RFs were identified. Of these, 1018 (34%) were identifiable from clinical history and examination alone (generalist setting) and 1961 (66%) by 12-lead electrocardiogram and echocardiography (cardiologist's office). Non-sarcomeric patients were diagnosed more often aged &lt;20 and after 60 years (476/500, 95%). Syndromic diseases such as Rasopathies, inherited metabolic disorders, and mitochondrial disorders were diagnosed in neonatal/early childhood (mean age 3 ± 2 years), whereas patients with Danon disease, Friedreich's ataxia, Noonan syndrome, and PRKAG2 cardiomyopathy were identified mostly during adolescence (mean age 16 ± 8 years). Non-cardiac RFs identified by clinical history, physical examination, and routine laboratory testing were most frequent in patients with HCM caused by Rasopathies, inherited metabolic disorders, and mitochondrial disorders (48%, 47%, and 57%, respectively). Physical RFs were almost exclusively observed in patients with a definite non-sarcomeric aetiology [348/350 (99%)]. On the contrary, most RFs associated with geno-positive and geno-negative HCM were derived from electrocardiogram and echocardiography [692/990 (70%) and 332/375 (88%), respectively].</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Red flags are a common finding in patients presenting with HCM, most commonly non-cardiac in non-sarcomeric aetiology and cardiac in sarcomeric HCM. Over 34% of RF, most relevant to rare HCM phenocopies, can be potentially detected in a generalist setting. Investing in high-touch-low tech, widespread awareness for HCM-related RF may provide substantial advantage in terms of diagnostic yield and appropriate use of resources.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928417/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39928417</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf026>10.1093/eurheartj/ehaf026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928417</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Niccolò Maurizi</dc:creator>
<dc:creator>Emanuele Monda</dc:creator>
<dc:creator>Elena Biagini</dc:creator>
<dc:creator>Ella Field</dc:creator>
<dc:creator>Silvia Passantino</dc:creator>
<dc:creator>Gabriella Dall' Aglio</dc:creator>
<dc:creator>Carlo Fumagalli</dc:creator>
<dc:creator>Panagiotis Antiochos</dc:creator>
<dc:creator>Ioannis Skalidis</dc:creator>
<dc:creator>Maurizio Pieroni</dc:creator>
<dc:creator>Alessia Argirò</dc:creator>
<dc:creator>Francesca Girolami</dc:creator>
<dc:creator>Franco Cecchi</dc:creator>
<dc:creator>Frederic Barbey</dc:creator>
<dc:creator>Pierre Monney</dc:creator>
<dc:creator>Perry M Elliott</dc:creator>
<dc:creator>Juan Pablo Kaski</dc:creator>
<dc:creator>Giuseppe Limongelli</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Hypertrophic cardiomyopathy: prevalence of disease-specific red flags</dc:title>
<dc:identifier>pmid:39928417</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf026</dc:identifier>
</item>
<item>
<title>Tricuspid and mitral regurgitation after mitral transcatheter edge-to-edge repair: a complex interplay</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928369/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 10:ehaf044. doi: 10.1093/eurheartj/ehaf044. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928369/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39928369</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf044>10.1093/eurheartj/ehaf044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928369</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Domenico Angellotti</dc:creator>
<dc:creator>Fabien Praz</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Tricuspid and mitral regurgitation after mitral transcatheter edge-to-edge repair: a complex interplay</dc:title>
<dc:identifier>pmid:39928369</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf044</dc:identifier>
</item>
<item>
<title>Meet the team: new EHJ Editors Matthias Endres, Ulrich Laufs, and Ranil De Silva</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928367/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 10:ehae929. doi: 10.1093/eurheartj/ehae929. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928367/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39928367</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae929>10.1093/eurheartj/ehae929</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928367</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Meet the team: new EHJ Editors Matthias Endres, Ulrich Laufs, and Ranil De Silva</dc:title>
<dc:identifier>pmid:39928367</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae929</dc:identifier>
</item>
<item>
<title>Prognosis following acute myocardial infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928355/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 10:ehaf056. doi: 10.1093/eurheartj/ehaf056. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928355/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39928355</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf056>10.1093/eurheartj/ehaf056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928355</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Iain B Squire</dc:creator>
<dc:creator>Shirley Sze</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Prognosis following acute myocardial infarction</dc:title>
<dc:identifier>pmid:39928355</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf056</dc:identifier>
</item>
<item>
<title>Pseudoxanthoma elasticum with cardiovascular involvement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39928354/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 10:ehaf022. doi: 10.1093/eurheartj/ehaf022. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39928354/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39928354</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf022>10.1093/eurheartj/ehaf022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39928354</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Tadahiro Kugai</dc:creator>
<dc:creator>Nobuhiro Tahara</dc:creator>
<dc:creator>Yoshihiro Fukumoto</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pseudoxanthoma elasticum with cardiovascular involvement</dc:title>
<dc:identifier>pmid:39928354</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf022</dc:identifier>
</item>
<item>
<title>Atrial cardiomyocyte-restricted cleavage of gasdermin D promotes atrial arrhythmogenesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39927987/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings establish a unique pyroptosis-independent role of NT-GSDMD in ACMs and arrhythmogenesis, which involves ROS-driven mitochondrial dysfunction. Mitochondrial-targeted therapy, either by reducing ROS production or inhibition of GSDMD, prevents AF inducibility, positioning GSDMD as a novel therapeutic target for AF prevention.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 10:ehaf024. doi: 10.1093/eurheartj/ehaf024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Enhanced inflammatory signalling causally contributes to atrial fibrillation (AF) development. Gasdermin D (GSDMD) is an important downstream effector of several inflammasome pathways. However, the role of GSDMD, particularly the cleaved N-terminal (NT)-GSDMD, in non-immune cells remains elusive. This study aimed to elucidate the function of NT-GSDMD in atrial cardiomyocytes (ACMs) and determine its contribution to atrial arrhythmogenesis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Human atrial appendages were used to assess the protein levels and localization. A modified adeno-associated virus 9 was employed to establish ACM-restricted overexpression of NT-GSDMD in mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The cleavage of GSDMD was enhanced in ACMs of AF patients. Atrial cardiomyocyte-restricted overexpression of NT-GSDMD in mice increased susceptibility to pacing-induced AF. The NT-GSDMD pore formation facilitated interleukin-1β secretion from ACMs, promoting macrophage infiltration, while up-regulating 'endosomal sorting complexes required for transport'-mediated membrane-repair mechanisms, which prevented inflammatory cell death (pyroptosis) in ACMs. Up-regulated NT-GSDMD directly targeted mitochondria, increasing mitochondrial reactive oxygen species (ROS) generation, which triggered proarrhythmic calcium-release events. The NT-GSDMD-induced arrhythmogenesis was mitigated by the mitochondrial-specific antioxidant MitoTEMPO. A mutant NT-GSDMD lacking pore-formation capability failed to cause mitochondrial dysfunction or induce atrial arrhythmia. Genetic ablation of Gsdmd prevented spontaneous AF development in a mouse model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings establish a unique pyroptosis-independent role of NT-GSDMD in ACMs and arrhythmogenesis, which involves ROS-driven mitochondrial dysfunction. Mitochondrial-targeted therapy, either by reducing ROS production or inhibition of GSDMD, prevents AF inducibility, positioning GSDMD as a novel therapeutic target for AF prevention.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39927987/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39927987</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf024>10.1093/eurheartj/ehaf024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39927987</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Yue Yuan</dc:creator>
<dc:creator>Pascal Martsch</dc:creator>
<dc:creator>Xiaohui Chen</dc:creator>
<dc:creator>Enrique Martinez</dc:creator>
<dc:creator>Luge Li</dc:creator>
<dc:creator>Jia Song</dc:creator>
<dc:creator>Theresa Poppenborg</dc:creator>
<dc:creator>Florian Bruns</dc:creator>
<dc:creator>Jong Hwan Kim</dc:creator>
<dc:creator>Markus Kamler</dc:creator>
<dc:creator>James F Martin</dc:creator>
<dc:creator>Issam Abu-Taha</dc:creator>
<dc:creator>Dobromir Dobrev</dc:creator>
<dc:creator>Na Li</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrial cardiomyocyte-restricted cleavage of gasdermin D promotes atrial arrhythmogenesis</dc:title>
<dc:identifier>pmid:39927987</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf024</dc:identifier>
</item>
<item>
<title>Wildfires, Compound Extreme Events, Climate Change, and Cardiovascular Health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39927913/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 21:S0735-1097(25)00136-6. doi: 10.1016/j.jacc.2025.01.009. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39927913/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39927913</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.009>10.1016/j.jacc.2025.01.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39927913</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Kai Chen</dc:creator>
<dc:creator>Yuan Lu</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Wildfires, Compound Extreme Events, Climate Change, and Cardiovascular Health</dc:title>
<dc:identifier>pmid:39927913</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.009</dc:identifier>
</item>
<item>
<title>Exploring Origin-Dependent Susceptibility of Smooth Muscle Cells to Aortic Diseases Through Intersectional Genetics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39925267/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our approach to genetically targeting SMC subtypes provides a novel platform for exploring origin-dependent or location-specific aortic vascular diseases. This genetic system enables comprehensive analysis of contributions from different cell lineages to SMC behavior and pathology, thereby paving the way for targeted research and therapeutic interventions in the future.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 10. doi: 10.1161/CIRCULATIONAHA.124.070782. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The developmental diversity among smooth muscle cells (SMCs) plays a crucial role in segment-specific aortic diseases. However, traditional genetic approaches are inadequate for enabling in vivo analysis of disease susceptibility associated with cellular origin. There is an urgent need to build genetic technologies that target different developmental origins to investigate the mechanisms of aortopathies, thereby facilitating the development of effective therapeutics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To address this challenge, we developed an advanced dual recombinase-mediated intersectional genetic system, specifically designed to precisely target SMCs from various developmental origins in mice. Specifically, we used <i>Isl1-Dre</i>, <i>Wnt1-Dre</i>, <i>Meox1-DreER</i>, and <i>Upk3b-Dre</i> to target SMC progenitors from the second heart field, cardiac neural crest, somites, and mesothelium, respectively. This system was combined with single-cell RNA sequencing to investigate the impact of TGF-β (transforming growth factor-β) signaling in different segments of the aorta by selectively knocking out Tgfbr2 in the ascending aorta and Smad4 in the aortic arch, respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Through intersectional genetic approaches, we use the <i>Myh11-Cre(ER</i>) driver along with origin-specific Dre drivers to trace cells of diverse developmental origins within the SMC population. We found that a deficiency of Tgfbr2 in SMCs of the ascending aorta leads to aneurysm formation in this specific region. We also demonstrate the critical role of Smad4 in preserving aortic wall integrity and homeostasis in SMCs of the aortic arch.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our approach to genetically targeting SMC subtypes provides a novel platform for exploring origin-dependent or location-specific aortic vascular diseases. This genetic system enables comprehensive analysis of contributions from different cell lineages to SMC behavior and pathology, thereby paving the way for targeted research and therapeutic interventions in the future.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39925267/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39925267</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070782>10.1161/CIRCULATIONAHA.124.070782</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39925267</guid>
<pubDate>Mon, 10 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Ximeng Han</dc:creator>
<dc:creator>Yi Li</dc:creator>
<dc:creator>Enci Wang</dc:creator>
<dc:creator>Huan Zhu</dc:creator>
<dc:creator>Xiuzhen Huang</dc:creator>
<dc:creator>Wenjuan Pu</dc:creator>
<dc:creator>Mingjun Zhang</dc:creator>
<dc:creator>Kuo Liu</dc:creator>
<dc:creator>Huan Zhao</dc:creator>
<dc:creator>Zixin Liu</dc:creator>
<dc:creator>Yufei Zhao</dc:creator>
<dc:creator>Linghong Shen</dc:creator>
<dc:creator>Yan Li</dc:creator>
<dc:creator>Xiao Yang</dc:creator>
<dc:creator>Qing-Dong Wang</dc:creator>
<dc:creator>Xin Ma</dc:creator>
<dc:creator>Ruling Shen</dc:creator>
<dc:creator>Kathy Lui</dc:creator>
<dc:creator>Lixin Wang</dc:creator>
<dc:creator>Ben He</dc:creator>
<dc:creator>Bin Zhou</dc:creator>
<dc:date>2025-02-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Exploring Origin-Dependent Susceptibility of Smooth Muscle Cells to Aortic Diseases Through Intersectional Genetics</dc:title>
<dc:identifier>pmid:39925267</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070782</dc:identifier>
</item>
<item>
<title>European Heart Agency: 12-year European Society of Cardiology presence in Brussels</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39923810/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 10:ehae879. doi: 10.1093/eurheartj/ehae879. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39923810/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39923810</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae879>10.1093/eurheartj/ehae879</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39923810</guid>
<pubDate>Sun, 09 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Panos E Vardas</dc:creator>
<dc:date>2025-02-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>European Heart Agency: 12-year European Society of Cardiology presence in Brussels</dc:title>
<dc:identifier>pmid:39923810</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae879</dc:identifier>
</item>
<item>
<title>Molecular basis of convergent evolution of ACE2 receptor utilization among HKU5 coronaviruses</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39922192/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>DPP4 was considered a canonical receptor for merbecoviruses until the recent discovery of African bat-borne MERS-related coronaviruses using ACE2. The extent and diversity of ACE2 utilization among merbecoviruses and their receptor species tropism remain unknown. Here, we reveal that HKU5 enters host cells utilizing Pipistrellus abramus (P.abr) and several non-bat mammalian ACE2s through a binding mode distinct from that of any other known ACE2-using coronaviruses. We defined the molecular...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 3:S0092-8674(24)01475-2. doi: 10.1016/j.cell.2024.12.032. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DPP4 was considered a canonical receptor for merbecoviruses until the recent discovery of African bat-borne MERS-related coronaviruses using ACE2. The extent and diversity of ACE2 utilization among merbecoviruses and their receptor species tropism remain unknown. Here, we reveal that HKU5 enters host cells utilizing Pipistrellus abramus (P.abr) and several non-bat mammalian ACE2s through a binding mode distinct from that of any other known ACE2-using coronaviruses. We defined the molecular determinants of receptor species tropism and identified a single amino acid mutation enabling HKU5 to utilize human ACE2, providing proof of principle for machine-learning-assisted outbreak preparedness. We show that MERS-CoV and HKU5 have markedly distinct antigenicity and identified several HKU5 inhibitors, including two clinical compounds. Our findings profoundly alter our understanding of coronavirus evolution, as several merbecovirus clades independently evolved ACE2 utilization, and pave the way for developing countermeasures against viruses poised for human emergence.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39922192/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39922192</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.032>10.1016/j.cell.2024.12.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39922192</guid>
<pubDate>Sat, 08 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Young-Jun Park</dc:creator>
<dc:creator>Chen Liu</dc:creator>
<dc:creator>Jimin Lee</dc:creator>
<dc:creator>Jack T Brown</dc:creator>
<dc:creator>Cheng-Bao Ma</dc:creator>
<dc:creator>Peng Liu</dc:creator>
<dc:creator>Risako Gen</dc:creator>
<dc:creator>Qing Xiong</dc:creator>
<dc:creator>Samantha K Zepeda</dc:creator>
<dc:creator>Cameron Stewart</dc:creator>
<dc:creator>Amin Addetia</dc:creator>
<dc:creator>Caroline J Craig</dc:creator>
<dc:creator>M Alejandra Tortorici</dc:creator>
<dc:creator>Abeer N Alshukairi</dc:creator>
<dc:creator>Tyler N Starr</dc:creator>
<dc:creator>Huan Yan</dc:creator>
<dc:creator>David Veesler</dc:creator>
<dc:date>2025-02-08</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Molecular basis of convergent evolution of ACE2 receptor utilization among HKU5 coronaviruses</dc:title>
<dc:identifier>pmid:39922192</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.032</dc:identifier>
</item>
<item>
<title>Multiple independent acquisitions of ACE2 usage in MERS-related coronaviruses</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39922191/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>The angiotensin-converting enzyme 2 (ACE2) receptor is shared by various coronaviruses with distinct receptor-binding domain (RBD) architectures, yet our understanding of these convergent acquisition events remains elusive. Here, we report that two bat MERS-related coronaviruses (MERSr-CoVs) infecting Pipistrellus nathusii (P.nat)-MOW15-22 and PnNL2018B-use ACE2 as their receptor, with narrow ortholog specificity. Cryoelectron microscopy structures of the MOW15-22/PnNL2018B RBD-ACE2 complexes...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 4:S0092-8674(24)01474-0. doi: 10.1016/j.cell.2024.12.031. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The angiotensin-converting enzyme 2 (ACE2) receptor is shared by various coronaviruses with distinct receptor-binding domain (RBD) architectures, yet our understanding of these convergent acquisition events remains elusive. Here, we report that two bat MERS-related coronaviruses (MERSr-CoVs) infecting Pipistrellus nathusii (P.nat)-MOW15-22 and PnNL2018B-use ACE2 as their receptor, with narrow ortholog specificity. Cryoelectron microscopy structures of the MOW15-22/PnNL2018B RBD-ACE2 complexes unveil an unexpected and entirely distinct binding mode, mapping >;45 Å away from that of any other known ACE2-using coronaviruses. Functional profiling of ACE2 orthologs from 105 mammalian species led to the identification of host tropism determinants, including an ACE2 N432-glycosylation restricting viral recognition, and the design of a soluble P.nat ACE2 mutant with potent viral neutralizing activity. Our findings reveal convergent acquisition of ACE2 usage for merbecoviruses found in European bats, underscoring the extraordinary diversity of ACE2 recognition modes among coronaviruses and the promiscuity of this receptor.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39922191/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39922191</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.031>10.1016/j.cell.2024.12.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39922191</guid>
<pubDate>Sat, 08 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Cheng-Bao Ma</dc:creator>
<dc:creator>Chen Liu</dc:creator>
<dc:creator>Young-Jun Park</dc:creator>
<dc:creator>Jingjing Tang</dc:creator>
<dc:creator>Jing Chen</dc:creator>
<dc:creator>Qing Xiong</dc:creator>
<dc:creator>Jimin Lee</dc:creator>
<dc:creator>Cameron Stewart</dc:creator>
<dc:creator>Daniel Asarnow</dc:creator>
<dc:creator>Jack Brown</dc:creator>
<dc:creator>M Alejandra Tortorici</dc:creator>
<dc:creator>Xiao Yang</dc:creator>
<dc:creator>Ye-Hui Sun</dc:creator>
<dc:creator>Yuan-Mei Chen</dc:creator>
<dc:creator>Xiao Yu</dc:creator>
<dc:creator>Jun-Yu Si</dc:creator>
<dc:creator>Peng Liu</dc:creator>
<dc:creator>Fei Tong</dc:creator>
<dc:creator>Mei-Ling Huang</dc:creator>
<dc:creator>Jing Li</dc:creator>
<dc:creator>Zheng-Li Shi</dc:creator>
<dc:creator>Zengqin Deng</dc:creator>
<dc:creator>David Veesler</dc:creator>
<dc:creator>Huan Yan</dc:creator>
<dc:date>2025-02-08</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Multiple independent acquisitions of ACE2 usage in MERS-related coronaviruses</dc:title>
<dc:identifier>pmid:39922191</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.031</dc:identifier>
</item>
<item>
<title>Novel pharmacological approaches to lowering blood pressure and managing hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39920248/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>Hypertension is the leading cause of death globally, primarily due to its strong association with cardiovascular disease. The global prevalence of hypertension has surged over the past three decades, driven by rising rates of diabetes mellitus and obesity. Despite current antihypertensive therapies, only a small proportion of patients with hypertension achieve adequate blood pressure control, necessitating novel therapeutic strategies. In this Review we explore the challenges and emerging...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Feb 7. doi: 10.1038/s41569-025-01131-4. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hypertension is the leading cause of death globally, primarily due to its strong association with cardiovascular disease. The global prevalence of hypertension has surged over the past three decades, driven by rising rates of diabetes mellitus and obesity. Despite current antihypertensive therapies, only a small proportion of patients with hypertension achieve adequate blood pressure control, necessitating novel therapeutic strategies. In this Review we explore the challenges and emerging opportunities in hypertension management. Aprocitentan, a dual endothelin receptor antagonist, is the first agent from a novel class of antihypertensive drug to be licensed since 2007 and exemplifies innovative treatments on the horizon. Here we also address the complex factors contributing to poor hypertension control, including genetic influences, lifestyle factors, therapeutic inertia and poor patient adherence. We discuss the limitations of existing therapies and highlight promising new pharmacological approaches to hypertension management. Integrating these novel treatments alongside current pharmaceuticals combined with improved diagnostic and management strategies could substantially reduce the global burden of hypertension and associated cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39920248/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39920248</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01131-4>10.1038/s41569-025-01131-4</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39920248</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Matthew Sayer</dc:creator>
<dc:creator>David J Webb</dc:creator>
<dc:creator>Neeraj Dhaun</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Novel pharmacological approaches to lowering blood pressure and managing hypertension</dc:title>
<dc:identifier>pmid:39920248</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01131-4</dc:identifier>
</item>
<item>
<title>Tracing the roots of cardiac fibrosis: role of endothelial-to-mesenchymal transition</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39920247/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250210214223&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Feb 7. doi: 10.1038/s41569-025-01134-1. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39920247/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250210214223&v=2.18.0.post9+e462414">39920247</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01134-1>10.1038/s41569-025-01134-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39920247</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Elizabeth Figueroa-Juárez</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Tracing the roots of cardiac fibrosis: role of endothelial-to-mesenchymal transition</dc:title>
<dc:identifier>pmid:39920247</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01134-1</dc:identifier>
</item>





























</channel>
</rss>